Results per Page:
House of cards: therapeutic vulnerabilities in the tumor microenvironment
From the Gujral Lab, Human Biology Division
Charting new territory in detangling cytokine secretion mechanisms
From the Gujral Lab, Human Biology Division
Degrade, degrade oncoproteins! PROTACs, a new strategy to kill cancer cells
From the Nabet Lab, Human Biology Division
Switching from KSHV latency to lytic replication
From the Geballe lab, Human Biology Division & Cancer Consortium
Diving into the dark kinome to identify synthetic lethal RAS therapeutic targets
From the Kemp Lab, Human Biology Division
Drug identified to combat Omicron-induced cytokine storm
From the Gujral Lab, Human Biology Division
Development of an in vitro model system to study tricky-to-target tumor microenvironment cells
From the Gujral Lab, Human Biology Division
Computational predictions reveal an unexpected synergy for prostate cancer therapy
From the Gujral Lab, Human Biology Division
Using AI to identify potential COVID-19, cancer therapies
Early findings show current drugs might be repurposed to calm COVID-19’s cytokine storms, treat metastatic prostate cancer
New cancer drugs lead to life-threatening financial choices
Hutch researchers in HICOR take on one of cancer treatment’s deadliest side effects, financial toxicity; call for Medicare policy change
Location, location, location: in situ phosphorylation screen reveals novel cell cycle kinase substrate landscape
From the Clurman Laboratory, Human Biology and Clinical Research Divisions